How Targeted Cancer Therapies Are Driving the MUC1 Antibody Market Growth According to a newly published market research report by 24LifeSciences, global MUC1 Antibody market is valued at USD 450 million in 2026 and is projected to reach USD 1,066 million by 2034, growing at a compound annual growth rate (CAGR) of 13.4% during the forecast period. MUC1 Antibodies are specialized immunoglobulins targeting Mucin 1, a transmembrane glycoprotein overexpressed in multiple carcinomas including breast, pancreatic, and ovarian cancers. These antibodies enable detection through techniques such as flow cytometry, ELISA, and immunohistochemistry, playing critical roles in cancer research, diagnostics, and therapeutic development. With breast cancer alone accounting for 2.3 million new cases globally in 2022 according to WHO data, the established importance of MUC1 as a biomarker continues to drive market expansion. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3018/muc-antibody-market-market

How AI and High-Throughput Screening Are Shaping the Cell Viability Assays Market According to a newly published market research report by 24LifeSciences, the global cell viability assays market value is at USD 2.58 billion in 2026 and is projected to reach USD 3.64 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.2% during the forecast period. Cell viability assays are essential laboratory techniques used to determine the proportion of living, healthy cells within a population. These assays function by measuring vital indicators such as metabolic activity, membrane integrity, and ATP content, which act as reliable proxies for cell health and function. Their application is fundamental across drug discovery, basic biomedical research, toxicology studies, and cancer research, providing critical data on how cells respond to new drug compounds, environmental toxins, or other experimental conditions. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8987/cell-viability-assays-market

Patient Derived Xenograft (PDX) Models Market Size to Reach USD 653 Million by 2032 Global Patient Derived Xenograft (PDX) Models market is witnessing strong momentum as precision oncology and personalized medicine reshape cancer drug development worldwide. Valued at USD 358 million in 2024, the market is projected to reach USD 653 million by 2032, expanding at a robust CAGR of 9.2% during the forecast period. Increasing demand for highly predictive preclinical models, coupled with rising oncology R&D investment, continues to position PDX models as a cornerstone of modern translational cancer research. Access the market report https://www.24lifesciences.com/patient-derived-xenograft-pdx-models-market-9495